Neuralstem (CUR) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Neuralstem Reports First Quarter 2015 Financial Results And Provides Business and Clinical Update
May 8, 2015 7:30 AM EDTGERMANTOWN, M.D., May 8, 2015 /PRNewswire/ --Â Neuralstem, Inc. (NYSE MKT: CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, reported its financial results for the three months ended March 31, 2015 and provided a business and clinical update.
"Neuralstem made substantial clinical progress this quarter in both our cell therapy and small molecule programs. We announced positive top-line safety data and encouraging secondary efficacy data for our Phase II ALS clinical trial, and look forward with anticipation to... More
Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer
May 6, 2015 7:31 AM EDTGERMANTOWN, Md., May 6, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced the appointment of Jonathan Lloyd Jones to the position of Chief Financial Officer, effective May 18th.
Mr. Lloyd Jones brings to the position more than 25 years of corporate finance and business development experience. Â Â Most recently, Mr. Lloyd Jones served as Chief Financial Officer at Columbia Laboratories (Juniper Pharmaceuticals), a Nasdaq-listed biotech company.... More
